RGS19 and cancer: Taken together, these results strongly supported the excellent anti-cancer effects of BRD4 inhibition by JQ1 in sunitinib-resistant ccRCC and suggested that SCG5, SPOCD1, RGS19, and ARHGAP22 may be novel direct targets of the epigenetic reader BRD4 in sunitinib-resistant ccRCC.